Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

Viking Therapeutics (NASDAQ:VKTX) stock is soaring on Thursday, extending the momentum it picked up in Wednesday's after‑hours session following the company's fourth‑quarter earnings release.

Viking Therapeutics Stock Soars: What's Driving The Momentum? ↗

February 12, 2026

Via Benzinga

Nasdaq, S&P 500 Futures Rise, Markets Await Jobless Claims: Why NVDA, META, NKTR, NVCR, AMAT, ASTS Are On Traders' Radar Today ↗

February 12, 2026

Viking (VKTX) Q4 2025 Earnings Call Transcript

Topics Stocks

Viking (VKTX) Q4 2025 Earnings Call Transcript ↗

February 11, 2026

Topics Earnings Intellectual Property

VKTX Shares Garner Retail Attention Ahead Of Q4 Earnings Report ↗

February 03, 2026

VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals ↗

January 14, 2026

Dow, S&P 500 Futures Climb As House Votes To Rescind Trump Tariffs: Why VKTX, NVCR, APP, CRM, QS Are Trending After-Hours ↗

February 11, 2026

The company shared optimistic timelines for advancing the clinical studies of both oral and subcutaneous VK2735 in obesity.

Topics Government Stocks

VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline ↗

February 11, 2026

Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore ↗

February 11, 2026

This stock has been known to soar after good news.

Could these two companies be biotech giants in the making?

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗

February 10, 2026

Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains? ↗

February 10, 2026

The stock has climbed in the triple digits over the past three years.

The most recent gold rush in weight loss drugs isn't done just yet.

3 Things Investors Need to Know About the Healthcare Sector in 2026 ↗

February 07, 2026

Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic Franchise Decouples from Competition

Topics Economy

February 06, 2026

Eli Lilly and Company (NYSE: LLY) has officially entered the "trillion-dollar club" with a roar, issuing a blockbuster financial guidance for 2026 that projects revenue between $80 billion and $83...

The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts

Topics Earnings Economy

February 05, 2026

In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a...

This pre-revenue biopharmaceutical stock is a home run swing worth taking.

Topics Earnings Economy

The Smartest Growth Stock to Buy With $30 Right Now ↗

February 03, 2026

They could perhaps see sustained runs beyond this year.

2 Biotech Stocks Set to Rebound in 2026 ↗

January 27, 2026

Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? ↗

January 26, 2026

Both companies may succeed in this industry.

It comes as no surprise that all three of them are capitalizing on relatively new, but game-changing, developments.

3 Growth Stocks to Invest $1,000 in Right Now ↗

January 24, 2026

Both could reward patient investors down the line.

Topics Artificial Intelligence

The Best Stocks to Invest $40 in to Start the New Year Off Right ↗

January 24, 2026

Date: January 23, 2026 Introduction In the high-stakes arena of metabolic medicine, few companies have generated as much speculative fervor and clinical awe as Viking Therapeutics (NASDAQ: VKTX). As of...

Topics Intellectual Property World Trade

Viking Therapeutics (VKTX) 2026 Deep Dive: Challenging the Obesity Duopoly

January 23, 2026

Via Finterra

Topics Intellectual Property

Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 ↗

January 23, 2026

This biotech has candidates in late-stage clinical development.

The Trillion-Dollar Heavyweight: Eli Lilly Surge Signals Unrivaled Dominance in the GLP-1 Era

January 22, 2026

Eli Lilly (NYSE: LLY) has once again demonstrated its resilience and market-leading strength, logging a significant 5.2% gain over the last five trading days as of January 22, 2026. This recent rally...

These stocks have struggled over the past year but may possess plenty of upside in the future.

Topics Economy

2 Bargain Stocks You Can Buy for Less Than $100 Right Now ↗

January 21, 2026

Can it become the next biotech leader?

1 Stock That Could Soar by 175%, According to Wall Street ↗

January 21, 2026

Despite a challenging year, the company has a lot to look forward to in the coming years.

What Happened to Viking Therapeutics in 2025, And Is it a Buy for 2026? ↗

January 20, 2026

As of January 19, 2026, the pharmaceutical landscape is being redefined by a single name: Eli Lilly and Company (NYSE: LLY). Once a steady, century-old stalwart known for its dominance in the insulin...

3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 ↗

January 20, 2026

Via MarketBeat

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All ↗

January 19, 2026

Via MarketBeat

Topics ETFs

The Trillion-Dollar Pharmacopeia: Eli Lilly’s (LLY) Dominance in the Age of Incretins

January 19, 2026

Via Finterra

Topics Economy

The Great Rotation: Small-Caps Log Longest Winning Streak Against S&P 500 Since 2019

January 12, 2026

As of mid-January 2026, the U.S. equity markets are witnessing a historic recalibration that few analysts predicted eighteen months ago. The Russell 2000 index, the benchmark for American small-cap...

What Investors Should Know About a Viking Therapeutics Insider's $2 Million Stock Sale ↗

Topics Artificial Intelligence Economy Stocks

January 11, 2026

This clinical-stage biotech developing metabolic therapies reported a notable insider sale amid a challenging year for its stock.